The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

20140103

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
ISSUE 1 – JAN. 3, 2014PDF

Who Makes This Drug?Secretive Contract Manufacturing Arrangements Complicate Solutions to Shortages of Generics

By Rena M. ContiThe closing of Ben Venue Laboratories, a company that produces a large share of generic drugs used by America’s oncologists, brings into focus a little-understood business practice that exacerbates the problem of drug shortages and shows why the industry and federal regulators have been unable to resolve them.
photoReport to the Nation: Death Rates Continue To Decline Across All Major Disease SitesDeath rates continued to decline for all cancers combined for men and women of all major racial and ethnic groups and for most major cancer sites, according to the Annual Report to the Nation on the Status of Cancer. Rates for both sexes combined decreased by 1.5 percent per year from 2001 through 2010.
photoAn Appreciation: Janet Rowley, “Translational Research Pioneer”Janet Rowley, a pioneer in connecting the development of cancer with genetic abnormalities, died from complications of ovarian cancer on Dec. 17 at her home. She was 88.
photoIn Brief
  • Julie Vose Elected President of ASCO
  • 2014 Breakthrough Prize Winners Announced
  • Andrea Sloan, Prominent Ovarian Cancer Patient Dies

YOU MAY BE INTERESTED IN

Clinical

Oncofertility coverage mandates expand to 21 states and DC as political momentum builds
Gaps persist as patients face harrowing decisions and huge copays

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

By Claire Marie Porter and Sara Willa Ernst
Guest Editorial

My introduction to, and lessons learned from, Rick Pazdur

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
By Mikkael A. Sekeres
Sponsored

Meeting the moment: ASCO GI Cancers Symposium delivers insights and collaboration

When it comes to fighting cancer today, collaboration is key. At a time when funding is uncertain, yet innovative breakthroughs are accelerating every day, it’s more important than ever for oncologists, scientists, academic researchers, and community physicians, to come together to share knowledge and gain insights about the forefront of cancer research.
By The American Society of Clinical Oncology

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account